Integrum, creator of the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA™) Implant System, has announced a major new contract with top ranked hospital NYU Langone Health.
NYU Langone Health is one of the biggest and highest regarded hospitals in the United States. It is consistently ranked as a top hospital in the country and the leading hospital system in New York.
The partnership is with NYU Langone’s Center for Amputation Reconstruction, part of NYU Langone’s orthopedic surgery program. The contract will enable physicians at the Center for Amputation Reconstruction to perform the two-step surgical procedure, called osseointegration, with Integrum’s OPRA™ Implant System. The first set of surgeries utilizing the OPRA Implant System were completed in August and November of 2022.
OTW spoke with U.S. President of Integrum Thomas Dugan about what sets the OPRA Implant System apart from its competition. Dugan told OTW, “Most amputees are traditionally fitted with a socket device, which can come with a number of daily challenges. Integrum’s OPRA™ Implant System provides amputees with a sense of normalcy they never thought possible, reducing skin pressure and sores, improving mobility and function, ensuring stability, and allowing a more comfortable and active lifestyle.”
Dugan continued, “It is the only FDA-approved bone-anchored technology designed specifically for amputees, connecting a prosthetic limb directly to the skeleton through a titanium implant and allowing the prosthesis to become a true extension of body and mind.”
The OPRA Implant System received FDA approval in 2020. Per NYU Langone Health’s press release, the system is approved for “people who have transfemoral, or above-knee, amputations and who have or are anticipated to have rehabilitation problems with, or cannot use, a conventional socket prosthesis.”
Omri B. Ayalon, M.D. and Jacques H. Hacquebord, M.D. lead the Center for Amputation Reconstruction and have led the OPRA Implant System surgeries. Nicola Fabbri, M.D., chief of the Division of Orthopedic Oncology, will facilitate the introduction of the OPRA Implant System as a treatment option for patients with bone cancer.
